Who Supplies Sitagliptin to India from UNITED STATES

Importing finished pharmaceutical formulations containing Sitagliptin into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs be registered and accompanied by an import license. The registration process involves submitting Form 40 or 41 to CDSCO, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Free Sale Certificate, and stability data. The timeline for obtaining registration and import licenses can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory reviews. For formulations under HS Code 30049099, specific requirements include demonstrating compliance with the Indian Pharmacopoeia standards and providing evidence of the drug's safety and efficacy.

Imported Sitagliptin formulations must undergo quality testing at CDSCO-approved laboratories to ensure they meet Indian standards. Batch-wise testing is mandatory, with each batch requiring a Certificate of Analysis (CoA) that confirms compliance with specified quality parameters. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's stability under India's climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported drugs. If a batch fails to meet the required standards, it may be rejected, leading to potential delays and additional costs for the importer.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical products, including mandatory registration and import licenses for all imported drugs. The Production Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, has impacted the import of finished formulations by encouraging local production. Bilateral agreements between India and the United States have facilitated smoother trade relations, but importers must stay updated on any policy changes that may affect the import process.

India imports finished Sitagliptin formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic pharmaceutical industry may lack the capacity to manufacture certain Sitagliptin formulations, leading to reliance on imports. The market size for Sitagliptin in India is substantial, with a growing number of patients requiring treatment for type 2 diabetes.

The import duty structure for Sitagliptin formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10%, and an Integrated Goods and Services Tax (IGST) of 12%. This results in a total landed duty of approximately 17.10%. Importers should also be aware of any anti-dumping duties or exemption notifications that may apply to specific products or countries of origin.

India sources Sitagliptin formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. The U.S. pharmaceutical industry offers advanced technology and compliance with international regulatory standards, providing a competitive advantage over other suppliers. While countries like China and Germany also supply Sitagliptin formulations, the United States maintains a significant share in the Indian market due to these factors.

India imports Sitagliptin formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. The U.S. pharmaceutical industry offers advanced technology and compliance with international regulatory standards, providing a competitive advantage over other suppliers. Specific formulations and dosage forms that are not manufactured domestically are sourced from the United States to meet patient needs.

When compared to other origins like China and the European Union, the United States offers advantages in terms of product quality, regulatory compliance, and reliability. While products from China may be more cost-effective, they may not always meet the stringent quality standards required by Indian regulators. The European Union provides high-quality products but may not offer the same range of specialized formulations as the United States. Therefore, the United States maintains a unique advantage in supplying Sitagliptin formulations to India.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to regulatory changes and quality control issues. Diversifying suppliers and maintaining adequate inventory levels can mitigate some of these risks.

1. 1Engage in dual-sourcing strategies to reduce dependency on a single supplier.
2. 2Implement robust inventory planning to manage supply chain disruptions.
3. 3Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Establish minimum order quantities (MOQs) that align with demand forecasts.
5. 5Conduct thorough supplier qualification processes to ensure compliance with regulatory standards.

1. 1Obtain a valid Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Submit Form 40 or 41 to CDSCO for registration of the drug.
3. 3Provide a Certificate of Pharmaceutical Product (CoPP) from the country of origin.
4. 4Secure a Free Sale Certificate from the manufacturer.
5. 5Provide stability data demonstrating compliance with ICH Zone IV conditions.
6. 6Obtain a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare, if required.
7. 7Engage a Customs House Agent (CHA) for customs clearance procedures.
8. 8Seek an advance ruling from Indian Customs for HS Code 30049099, if necessary.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF) for the product.
5. 5Stability data under ICH